SCHEMBL21632147

SCHEMBL21632147

CC(CN)(CCC(=O)O)c1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 9/20 0.44
L3MBTL1 Q9Y468 1/20 0.40
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
ADRA1A P35348 1/20 0.38
OPRK1 P41145 1/20 0.38
KCNH2 Q12809 1/20 0.38
KIF11 P52732 1/20 0.38
KCNN4 O15554 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
ALDH1A1 P00352 1/20 0.37
ESR1 P03372 1/20 0.37
CYP3A4 P08684 1/20 0.37
ESR2 Q92731 1/20 0.37
LMNA P02545 1/20 0.36
CHEK1 O14757 1/20 0.35
FYN P06241 1/20 0.35
PDGFRB P09619 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21632132 0.91 PTGFR (0.46) PTGFRL3MBTL1HTR2AHTR2CADRA1A
SCHEMBL21631955 0.84 CYP2C19 (0.51) PTGFRL3MBTL1HTR2AHTR2CADRA1A
SCHEMBL21656603 0.83 L3MBTL1 (0.36) PTGFRL3MBTL1HTR2AHTR2CADRA1A
SCHEMBL20535152 0.81 HTR2A (0.42) PTGFRHTR2AHTR2CADRA1AOPRK1
SCHEMBL21632116 0.80 PTGFR (0.46) PTGFRHTR2AHTR2CCYP2C19ALDH1A1
SCHEMBL27629791 0.79 HIF1A (0.56) KIF11CYP2C19HIF1AALDH1A1ESR1
SCHEMBL21656375 0.78 PTGFR (0.36) PTGFRL3MBTL1HTR2AHTR2CADRA1A
SCHEMBL21632134 0.75 HTR2A (0.38) PTGFRHTR2AHTR2CADRA1AOPRK1
SCHEMBL21632104 0.74 KCNN4 (0.42) PTGFRL3MBTL1HTR2AHTR2CADRA1A
SCHEMBL21656363 0.74 CYP2C19 (0.36) L3MBTL1KIF11KCNN4CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136296-B2 Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-10-05 US disclosed
US-20200031775-A1 SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031775-A1 SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF AADAC, NAT1, EPX PTGFR 1050/4885L3MBTL1 3686/4885HTR2A 1228/4885
US-11136296-B2 Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof AADAC, NAT1, EPX PTGFR 1050/4885L3MBTL1 3686/4885HTR2A 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.